Publications

Key Publications

1. Huang J, Kelly CP, Bakirtzi K, Villafuerte Galvez JA, Lyras, D, Mileto SJ, Larcombe S, Hu H, Yang X, Shields KS, Zhu W, Zhang Y, Goldsmith JD, Patel IJ, Hansen J, Huang M, Yla-Herttuala S, Moss AC, Paredes-Sabja D, Pothoulakis C, Shah YM, Wang J, Chen X, Clostridium difficile toxins induce VEGF-A and vascular permeabiloty to promote disease pathogenesis, Nature Microbiology, https://doi.org/10.1038/s41564-018-0300-x
2. Wang J, Ghali S, Mussatto CC, Ortiz C, Lee EC, Tran DH, Jacobs JP, Lagishetty V, Faull KF, Moller T, Rossetti M, Chen X, HKoon HW, Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites, Gastroenterology, 2018 Jan 31, Jan 31. pii: S0016-5085(18)30067-2. doi: 10.1053/j.gastro.2018.01.026. [Epub ahead of print]
3. Hoffman JM, Sideri A, Ruiz JJ, Stavrakis D, Shih DQ, Turner JR, Pothoulakis C, Karagiannides I, Mesenteric adipose-derived stromal cells from Crohn’s Disease patients induce protective effects in colonic epithelial cells and mice with colitis, Cellular and Molecular Gastroenterology and Hepatology (2018), doi: 10.1016/j.jcmgh.2018.02.001
4. Koon HW, Wang J, Mussatto CC, Ortiz C, Lee EC, Tran DH, Chen X, Kelly CP, Pothoulakis C. Fidaxomicin and OP-1118 inhibit C. difficile toxin A- and B-mediated inflammatory responses via inhibition of NF-κB activity. Antimicrob Agents Chemother, 2017; Oct 16. pii: AAC.01513-17. doi: 10.1128/AAC.01513-17
5. Padua D, Mahurkar-Joshi S, Law IKM, Polytarchou C, Vu JP, Pisegna JR, Shih D, Iliopoulos D, Pothoulakis C. A long noncoding RNA signature for ulcerative colitis identifies IFNG-AS1 as an enhancer of inflammation. Am J Physiol, 2016; 311(3):G446-57
6. Koon HW, Su B, Xu C, Mussatto CC, Tran DH-N, Lee EC, Lee JE, Ho S, Chen X, Kelly CP, Pothoulakis C. Probiotic Saccharomyces boulardii CNCM I-745 inhibits hypervirulent Clostridium difficile-associated cecal tissue damage and pro-inflammatory cytokine expression in hamsters. Am J Physiol, 2016; 311(4):G610-G623
7. Bakirtzi K, Law I, Xue X, Iliopoulos D, Shah YM , Pothoulakis C. Neurotensin promotes the development of colitis and intestinal angiogenesis via HIF-1α-miR-210 signaling. J Immunol. 2016; 196(10):4311-21
8. Law IKM, Jensen D, Bunnett NW, Pothoulakis C. Neurotensin-induced miR-133α expression regulates neurotensin receptor 1 recycling through its downstream target aftiphilin. In revised form, Sci Reports. 2016; 6:22195
9. Hoffman JM, Baritaki S, Ruiz JJ, Sideri A, Pothoulakis C. Corticotropin-releasing hormone receptor 2 signaling promotes mucosal repair responses following colitis. Am J Pathol. 2016; 186(1):134-44
10. Fang K, Sideri A, Law IKM, Bakirtzi K, Polytarchou C, Iliopoulos D, Pothoulakis C. Identification of a novel substance P (SP)-neurokinin-1 receptor (NK-1R) microRNA-221-5p inflammatory network in human colonic epithelial cells. Cell Mol Gastroenterol Hepatol. 2015; 1(5):503-515
11. Sideri A, Bakirtzi K, Shih DQ, Koon HW, Fleshner P, Arsenescu R, Arsenescu V, Turner JR, Karagiannides I, Pothoulakis C. Substance P mediates pro-inflammatory cytokine release form mesenteric adipocytes in patients with Inflammatory Bowel Diseases. Cell Mol Gastroenterol Hepatol. 2015; 1:420-432
12. Im E, Jung J, Pothoulakis C, Rhee SH. Disruption of Pten speeds onset and increases severity of spontaneous colitis in Il10(-/-) mice. Gastroenterology 2014;147(3):667-679
13. Bakirtzi K, West G, Fiocchi C, Iliopoulos D, Pothoulakis C. The neurotensin-HIF-1α-VEGFα axis orchestrates hypoxia, colonic inflammation, and intestinal angiogenesis. Am J Pathol 2014; 184(12):3405-14
14. Law IKM, Bakirtzi K, Polytarchou C, Iliopoulos D, and Pothoulakis C. Neurotensin – regulated miR-133α is involved in proinflammatory signaling in human colonic epithelial cells and in experimental colitis. Gut 2014 Aug 11. pii: gutjnl-2014-307329. doi: 10.1136/gutjnl-2014-307329
15. Savidge TC, Urvil P, Oezguen N, Kausar A, Choudhury A, Acharya V, Pinchuk I, Torres AG, English RD, Wiktorowicz JE, Leoffelholz M, Kumar R, Shi L, Nie W, Feng H, Braun W, Herman B, Stamler JS, Pothoulakis C. Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins. Nature Medicine; 2011; 17(9):1136-41
16. Bakirtzi K, Hatziapostolou M, Karagiannides I, Polytarchou C, Jaeger S, Dry S, Iliopoulos D*, Pothoulakis C*. Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors. *equally contributing senior authors. Gastroenterology 2011; 141:1749-1761
17. Karagiannides I, Torres D, Tseng Y-H, Bowe C, Espinoza D, Pothoulakis C * Kokkotou.* Substance P as a novel anti-obesity target. * Equally contributing senior authors. Gastroenterology 2008; 134(3):747-55
18. Koon H-W, Kim YS, Xu H, Zhan Y, Zhao D, Karagiannides I, Dobner PR, Pothoulakis C. Neurotensin induces IL-6 secretion in mouse preadipocytes and adipose tissues during 2,4,6,-trinitrobenzensulphonic acid-induced colitis. Proc Natl Acad. Sci, (USA) 2009; 106(21):8766-71
19. Kokkotou E, Moss AC, Torres D, Karagiannides I, Cheifetz A, Liu S, O’Brien M, Maratos-Flier E, Pothoulakis C. Melanin-Concentrating Hormone as a mediator of intestinal inflammation. Proc Natl Acad Sci (USA) 2008; 105:10613-8
20. Koon HW, Zhao D, Zhan Y, Moyer MP, Pothoulakis C. Substance P mediates antiapoptotic responses in human colonocytes by Akt activation. Proc Natl Acad Sci (USA) 2007; 104:2013-8
21. Castagliuolo I, Wang C-C, Valenick L, Pasha A, Nikulasson S, Carraway RE, Pothoulakis C. Neurotensin is a proinflammatory peptide in colonic inflammation. J Clin Invest 1999;103:843-849
22. Castagliuolo I, Riegler M, Nikulasson S, Lu B, Gerard C, Gerard NP, Pothoulakis C. NK-1 receptor is required in Clostridium difficile- induced enteritis. J. Clin. Invest 1998;101:1547-50